Literature DB >> 26199397

Bortezomib in refractory ANCA-associated vasculitis: a new option?

Pavel Novikov1, Sergey Moiseev1, Nikolay Bulanov1, Elena Shchegoleva1.   

Abstract

Entities:  

Keywords:  Systemic Lupus Erythematosus; Systemic vasculitis; Treatment

Mesh：

Substances：

Year:  2015        PMID： 26199397     DOI： 10.1136/annrheumdis-2015-207947

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

Review 1.  Treatment of membranous nephropathy: time for a paradigm shift.

Authors:  Piero Ruggenenti; Fernando C Fervenza; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

Review 2.  Plasma cells as an innovative target in autoimmune disease with renal manifestations.

Authors:  Falk Hiepe; Andreas Radbruch
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

Review 3.  Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives.

Authors:  Eva Schrezenmeier; David Jayne; Thomas Dörner
Journal:  J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 10.121

Review 4.  Diagnostic and Therapeutic Approach in ANCA-Associated Glomerulonephritis: A Review on Management Strategies.

Authors:  Adél Molnár; Péter Studinger; Nóra Ledó
Journal:  Front Med (Lausanne)       Date:  2022-06-03

5.  Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis.

Authors:  Hiroshi Maruyama; Kouichi Hirayama; Marina Yamashita; Kentaro Ohgi; Ryuji Tsujimoto; Mamiko Takayasu; Homare Shimohata; Masaki Kobayashi
Journal:  BMC Rheumatol       Date:  2020-08-25

Review 6.  Pathogenesis and therapeutic interventions for ANCA-associated vasculitis.

Authors:  Daigo Nakazawa; Sakiko Masuda; Utano Tomaru; Akihiro Ishizu
Journal:  Nat Rev Rheumatol       Date:  2019-02       Impact factor: 20.543

Review 7.  Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Nephrol       Date:  2018-05-06

8.  Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies.

Authors:  Joseph M Rocco; Lindsey B Rosen; Gloria H Hong; Jennifer Treat; Samantha Kreuzburg; Steven M Holland; Christa S Zerbe
Journal:  J Transl Autoimmun       Date:  2021-05-04

9.  Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience.

Authors:  Christiane Schneider-Gold; Anke Reinacher-Schick; Gisa Ellrichmann; Ralf Gold
Journal:  Ther Adv Neurol Disord       Date:  2017-07-26       Impact factor: 6.570

Review 10.  Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?

Authors:  Devis Benfaremo; Armando Gabrielli
Journal:  Cells       Date:  2019-12-27       Impact factor: 6.600
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.